NAMS — NewAmsterdam Pharma Company NV

Ownership history in Siren, L.L.C. · 5 quarters on record

This page tracks every 13F SEC filing in which Siren, L.L.C. reported a position in NewAmsterdam Pharma Company NV (NAMS). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position

2.38% (2024 Q4)

Avg. % of fund

1.47%

First filed

2024 Q3

Last filed

2025 Q3

Quarters held

5

Quarter	Action	Shares	Change	Chg %	% of Fund	Mkt Value	Price (EOQ)
2025 Q3	REDUCED	765,705	-428,535	-35.9%	0.85%	$21.8M	$28.44
2025 Q2	REDUCED	1,194,240	-717,790	-37.5%	1.12%	$21.6M	$18.11
2025 Q1	REDUCED	1,912,030	-183,608	-8.8%	2.23%	$39.1M	$20.47
2024 Q4	ADDED	2,095,638	+1,175,074	+127.6%	2.38%	$53.9M	$25.70

% of Fund (quarterly) NAMS price (monthly, adj. close)

Other funds also holding NAMS

As of 2025 Q4 — sorted by position size

FCPM III SERVICES B.V. 42.3% Bain Capital Life Sciences Investors, LLC 3Y 7Y 19.63% Frazier Life Sciences Management, L.P. 3Y 15.96% Medicxi Ventures Management (Jersey) Ltd 3Y 12.06% First Turn Management, LLC 3.58% RA CAPITAL MANAGEMENT, L.P. 3Y 7Y 3.43% Decheng Capital LLC 2.79% Artia Global Partners LP 3Y 2.5% Duquesne Family Office LLC 3Y 7Y 2.4% Atle Fund Management AB 3Y 7Y 2.21%

← Back to Siren, L.L.C. Holdings